Technology

ACCESS MEDICAL LABS CONFIRMS ELIZABETH HOLMES EXACT PFIZER STUDY RESULTS USING THE SAME COMPONENTS

Published

2 years ago

February 28, 2025

JUPITER, Fla., Feb. 28, 2025 /PRNewswire/ — In a stunning revelation that will reshape the conversation around Elizabeth Holmes and her work at Theranos, one of the largest Specialty Labs in the Nation has confirmed that Holmes’ diagnostic technology was in fact Accurate—and that her suppressed Test Result findings regarding Avastin®, a cancer drug were very accurate during the 15 month Pfizer study in 2007.

In 2007 and 2008, Holmes conducted a study for Pfizer investigating the angiogenesis process and the effect of Bevacizumab, an anti-VEGF antibody therapy used in cancer treatment under the brand name, Avastin® https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%200143/Trial%20Exh.%200143%20Email.pdf

See page 0012 of Trial exhibit 0143. – bottom half of 0012 shows the Avastin® affect.

The Pfizer contract with Theranos was executed on December 12th 2006 worth $900,000.00. https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%2014112/Trial%20Exh.%2014112%20Agreement.pdf

The study took place in clinics and in patient homes with her machine wirelessly transmitting Results to Theranos servers and the Pfizer portal during the course.

Her research demonstrated that while the drug initially appeared to suppress VEGF levels, that was only true using another companies reagent that is used by LabCorp and many labs across the nation called, R&D Systems VEGF ELISA. Avastin® is a monoclonal antibody that attaches to VEGF in the body to prevent the body from making blood vessels (angiogenesis) so the cancer will not spread. The problem is, ELISA testing using Antibodies, in fact the same antibody as Avastin, Anti-VEGF or better known as Bevacizumab. This causes a problem when testing for VEGF because you cannot detect it due to the same antibody being present. It doesn’t know VEGF is present, it is being blocked by Anti-VEGF.

She also discovered that Avastin causes what’s called a VEGF complex, which means the body starts creating TONS of VEGF. VEGF levels spiked dramatically—showing an alarming surge from an average of 140 pg/mL to over 8,000 pg/mL. This post-treatment VEGF REBOUND effect signals a rapid increase in blood vessel formation, which could exacerbate cancer proliferation rather than control it. Her study was also confirmed independently in 2023 by JAMA open network. https://www.cancertherapyadvisor.com/news/discontinuation-of-bevacizumab-in-ovarian-cancer-may-result-in-rebound/

Despite Holmes’ findings, Pfizer and Dr. Shane Weber who testified against Elizabeth Holmes in court, rejected the results on December 31st 2008. https://files.cand.uscourts.gov/files/18-CR-258%20USA%20v.%20Holmes/Trial%20Exh.%200167/Trial%20Exh.%200167%20Report.pdf

Holmes’ research was originally conducted using the Theranos Edison (TSPU – Theranos System Processing Unit), which ran proprietary assays to measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued.

Holmes’ Study was originally conducted using the Edison or aka the TSPU – Theranos Systems Processing Unit, which ran proprietary assays developed in house at Theranos and commercially available test kits used by Lab Giants, LabCorp and Quest. In this case of VEGF, she used her proprietary test measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued because she could detect the TOTAL VEGF.

Today, Access Medical Labs has demonstrated that:

Holmes’ technology was indeed Accurate.Conventional testing methods, such as those used by LabCorp may underreport the true impact of anti-VEGF drugs.When Bevacizumab exits the bloodstream, a VEGF rebound may occur and CANNOT be detected early enough due to VEGF being blocked which could drastically increase the spread of cancer.Our lab testing proves that Elizabeth Holmes did not lie. Her tests & machine worked.

Ryan ElHosseiny
Access Medical Labs
954-494-1664
www.accessmedlab.com

View original content:https://www.prnewswire.com/news-releases/access-medical-labs-confirms-elizabeth-holmes-exact-pfizer-study-results-using-the-same-components-302389018.html

SOURCE Access Medical Labs

Technology

Industry leaders to join forces to scale hydrogen mobility

Published

34 minutes ago

September 3, 2026

Volvo Group

For the first time in Europe, Germany is bringing together the full ecosystem needed to scale the deployment of hydrogen trucks by 2030, combining supportive policy frameworks, a strong OEM offering and an integrated hydrogen supply chain and infrastructure.Volvo Group, Daimler Truck, Toyota Motor Corporation, Bosch, Air Liquide, TotalEnergies, TEAL Mobility, MB Energy, and more companies accelerate the commercialization of hydrogen-powered mobility and build the ecosystem needed to scale it along the whole value chain, with vehicles, infrastructure and supply. The activities include the deployment of hydrogen refueling stations along key strategic corridors in Europe, in synchronization with the hydrogen-powered truck fleets as well as a competitive hydrogen price. This will enable customers to operate hydrogen-powered vehicles with a competitive total cost of ownership. Full details will be unveiled at a CEO-led press event during IAA Transportation in Hanover on 15 September.

GOTHENBURG, Sweden, Sept. 3, 2026 /PRNewswire/ — Leading companies from the transport, energy and industrial sectors, together with German policymakers, are collaborating to establish a benchmark for a fully integrated hydrogen mobility ecosystem for heavy-duty transport. They reflect a shared ambition to scale hydrogen with a focus on customer-oriented refueling infrastructure and competitively priced hydrogen fuel.

Delivering a comprehensive hydrogen ecosystem that complements battery-electric solutions requires coordinated development across the entire value chain with focus on commercializing competitive vehicles, deploying strategically located refueling infrastructure aligned with customer needs, and ensuring reliable access to hydrogen at viable price levels. Together, these elements can create the conditions for a competitive total cost of ownership and position hydrogen as a practical, scalable solution for zero-emission transport.

Further details will be announced on September 15 at IAA Transportation 2026.

Volvo Group, Daimler Truck, Toyota Motor Corporation, Bosch, Air Liquide, TotalEnergies, TEAL Mobility, MB Energy

September 3, 2026

Journalists wanting further information, please contact:
Claes Eliasson, Head of Media Relations
+46 76 553 7229
press@volvo.com

For more information, please visit volvogroup.com
For frequent updates, follow us on LinkedIn

The Volvo Group drives prosperity through transport and infrastructure solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs almost 100,000 people and serves customers in almost 180 markets. In 2025, net sales amounted to SEK 479 billion (EUR 43 billion). Volvo shares are listed on Nasdaq Stockholm.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/ab-volvo/r/industry-leaders-to-join-forces-to-scale-hydrogen-mobility,c4391363

The following files are available for download:

https://mb.cision.com/Main/39/4391363/4249230.pdf

Press release â€” Industry leaders to join forces to scale hydrogen mobility

https://news.cision.com/ab-volvo/i/1860×1050-iaa-pr,c3561719

1860×1050 IAA PR

View original content:https://www.prnewswire.com/news-releases/industry-leaders-to-join-forces-to-scale-hydrogen-mobility-302868716.html

SOURCE AB Volvo

Technology

CFD Broker Mitrade EU Introduces Excess-of-Loss Insurance Protection for Its Clients

Published

34 minutes ago

September 3, 2026

LIMASSOL, Cyprus, Sept. 3, 2026 /PRNewswire/ — CFD broker Mitrade has arranged additional insolvency insurance for eligible clients onboarded under its CySEC licence. The initiative reflects a broader focus on strengthening client confidence and investor protection.

This excess-of-loss policy supplements protections CySEC already mandates. CySEC-authorised investment firms are required to segregate client funds and contribute to the Investor Compensation Fund. Beyond those statutory safeguards, Mitrade EU Limited’s discretionary insurance coverage has been arranged through Lloyd’s of London and funded by Mitrade. It is automatically available to eligible clients without an opt-in requirement or additional client charge.

Should Mitrade EU Limited become insolvent, the policy may cover eligible claims, subject to its terms, conditions and exclusions, up to a maximum aggregate amount of €1 million across all claims combined. It does not cover trading losses or losses caused by market movements.

“Regulation sets the baseline; we decide how much further to go for clients,” said Timur Konsky, CEO of Mitrade EU. “That is why we put additional insurance in place with Lloyd’s of London. Our approach is to identify where clients can be protected and take steps to reduce those risks. Transparency and safety should not be marketing language; they should be demonstrated through the safeguards a broker chooses to put in place. We want our clients to judge us by our actions, and this policy is another concrete example of that commitment.”

Mitrade EU’s excess-of-loss insurance cover takes effect from 1 September 2026.

About Mitrade

Mitrade is a CFD trading platform operating in eligible EEA markets through Mitrade EU Limited, a CySEC-authorised investment firm (CIF438/23). Other legally separate entities within the international group are independently authorised and regulated in their respective jurisdictions by ASIC (AFSL398528), CIMA (SIB1612446), FSCA (FSP54842), FSC (GB20025791), and CMA (20200000397).

Globally, the brand connects 7M+ traders to 1,000+ CFDs on indices, forex, commodities, shares, ETFs and more. The platform is designed to provide fast execution, flexible leverage on a per-position basis, competitive spreads and an intuitive interface accessible across multiple devices.

Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Visit https://www.mitrade.eu for more information.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cfd-broker-mitrade-eu-introduces-excess-of-loss-insurance-protection-for-its-clients-302867016.html

Technology

Aurra Markets Receives ‘Most Transparent Broker’ Award in Mumbai

Published

34 minutes ago

September 3, 2026

Aurra Markets wins the ‘Most Transparent Broker’ award at Money Expo Mumbai 2026. Read about our MT5 infrastructure and Aurra Wallet.

MUMBAI, India, Sept. 3, 2026 /PRNewswire/ — Aurra Markets Wins ‘Most Transparent Broker’ Award at Money Expo Mumbai

Aurra Markets, a multi-asset CFD broker, received the ‘Most Transparent Broker’ award at Money Expo Mumbai 2026. Participating as a Diamond Sponsor at the Jio World Convention Centre, the brokerage presented its institutional-grade trading infrastructure and partnership models to the Indian financial community.

Direct Market Access and Tier-1 Liquidity

Receiving this award reflects the company’s focus on maintaining secure trading conditions. In active financial markets, reliability is a primary requirement for retail and institutional traders. By integrating direct Tier-1 liquidity and holding fully segregated client funds, Aurra Markets provides a stable environment for trading forex, precious metals, and indices. The team demonstrated its MetaTrader 5 (MT5) framework at Booth 33, highlighting the 12ms execution speed that supports algorithmic and day traders.

Efficient Funding via the Aurra Wallet

The exhibition also served as a platform to detail the company’s advanced funding infrastructure. Clients can manage their capital using the Aurra Wallet. This unified system bridges fiat and digital assets, allowing traders to handle deposits and withdrawals efficiently. Integrating this technology reduces banking delays and provides rapid market access.

Expanding Operations in the Indian Market

“We are honored to receive the Most Transparent Broker award in Mumbai,” a senior spokesperson for Aurra Markets stated. “This recognition validates our infrastructural investments designed to lower trading costs and maintain security. Engaging with affiliates and traders in India confirms the demand for high-performance trading solutions. We provide market participants with the stability needed to trade macroeconomic shifts.”

About Aurra Markets

Aurra Global Markets Limited is authorized and regulated by the Mauritius Financial Services Commission (FSC) under License No. GB25204837. Aurra Markets provides a global community of traders with the direct infrastructure and technical resources needed to operate in dynamic financial markets. For more information, visit www.aurra.markets.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurra-markets-receives-most-transparent-broker-award-in-mumbai-302868741.html

SOURCE AURRA GLOBAL MARKETS LIMITED